Avalyn Pharma Inc. Common Stock

NASDAQ:AVLN

Medical - Pharmaceuticals

Healthcare
$27.69 +1.77%

+$0.52 today

Market cap
$1.23B
Beta
0.00
52W Low $24.15High $32.23

Volume 0.40M

Average 0.51M

AVLN Research & Development

Spending on developing new products, technologies, and improvements to existing offerings.

No reported Research & Development figures are available to summarize.

Research & Development history

Currency unavailable · from the income statement

No Research & Development data reported for this period type.

Research & Development vs competitors

How AVLN compares with its peers on the latest reported figures

AVLN Competitors
Research & Development for AVLN and competitors
Company Period LTM YoY 3-year CAGR% of revenue
INSMInsmed IncorporatedLTM Jun 2026$860.85M USD+30.4%+24.7%75.7%
VCREVicore Pharma Holding ABLTM Jun 2026SEK 238.42M SEK+2.0%+16.0%17927.0%
MNKDMannKind CorporationLTM Mar 2026$72.56M USD+54.7%+49.8%20.1%
GYREGyre Therapeutics, Inc.LTM Mar 2026$17.34M USD+34.0%-6.4%14.8%
AVLNAvalyn Pharma Inc. Common Stock—— ———
Peer median (excluding AVLN) —+32.2%+20.4%47.9%

Competitors are the stored peer set for AVLN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Avalyn Pharma Inc. Common Stock

NASDAQ:AVLN

Intrinsic Alpha fair value

Locked

Current Price

$27.69

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.